A population-based study of colorectal cancer risk in patients with type 2 diabetes mellitus: pathophysiological characteristics and outcomes

Colorectal cancer is a disease that affects the large intestine and the rectum, and despite being preventable in many cases, it remains a leading cause of death worldwide. Scientists have long known that lifestyle factors like smoking, poor diet, and lack of exercise play a major role in its development. In recent years, attention has turned toward metabolic health, specifically the relationship between the body's ability to manage sugar and the risk of developing this cancer. Type 2 diabetes is a condition where the body struggles to regulate blood sugar levels, often leading to high concentrations of glucose in the blood. Because diabetes and cancer share common risk factors like obesity and high blood pressure, researchers have wondered if having diabetes might make colorectal cancer more aggressive or harder to treat. Understanding this link is crucial because millions of people live with diabetes, and knowing how it interacts with cancer could help doctors identify who is at higher risk and tailor their care accordingly.

A team of researchers in Tianjin, China, set out to investigate this connection by looking at the medical records of 1,436 patients who had undergone surgery for colorectal cancer at their hospital in 2018. They wanted to see if patients who also had type 2 diabetes, or even just high fasting blood sugar levels, had different cancer characteristics compared to those without these metabolic issues. The researchers carefully reviewed details about the patients' ages, body weights, and other health conditions, as well as the specific features of their tumors, such as how far they had spread and whether they had reached the lymph nodes. They divided the patients into groups based on whether they had a confirmed diagnosis of type 2 diabetes or simply had high blood sugar readings at the time of their surgery.

The study revealed a clear pattern: patients with type 2 diabetes were more likely to have cancer that was already at a more advanced stage when it was discovered. Specifically, nearly half of the patients with diabetes had tumors that had spread to nearby lymph nodes or other parts of the body, a stage known as III or IV. In contrast, a smaller portion of patients without diabetes had reached this advanced stage. This difference was statistically significant, suggesting that the presence of diabetes is an independent factor that pushes the disease toward a more severe condition at the time of diagnosis. The researchers also found that patients with diabetes were more likely to have elevated levels of a protein called CEA, which is often used as a marker to track cancer activity, further hinting that the disease might be more active in these individuals.

Interestingly, the researchers noticed that this link between diabetes and advanced cancer was much stronger in men than in women. When they looked at the data separately for each gender, they found that male patients with diabetes were significantly more likely to have advanced tumors compared to men without diabetes. For women, however, the presence of diabetes did not show the same strong association with the cancer's stage. This suggests that the biological interplay between diabetes and cancer might work differently depending on a person's sex, possibly due to differences in how hormones or body fat are distributed. The study also looked at patients who did not have a formal diabetes diagnosis but still had high blood sugar levels. These patients showed similar trends to those with confirmed diabetes, indicating that even undiagnosed high blood sugar might be a warning sign for more aggressive cancer behavior.

Despite finding that diabetes is linked to more advanced cancer at the time of surgery, the study did not find that it directly shortened the lives of the patients after they had been treated. The researchers tracked the patients for five years following their operations and found that the overall survival rates were very similar between those with diabetes and those without. This means that while diabetes might make the cancer more dangerous to begin with, it does not necessarily mean that patients with diabetes will die sooner from the disease if they receive proper surgical treatment. The results suggest that the primary drivers of survival are the stage of the cancer and its specific biological features, rather than the patient's diabetic status alone.

The findings of this study offer a practical insight for doctors and patients. It highlights that for men with type 2 diabetes, colorectal cancer may be more likely to be found at a later, more serious stage. This implies that these individuals might benefit from more vigilant screening and closer monitoring to catch the disease earlier. The study also underscores the importance of managing blood sugar levels, as high glucose appears to be associated with more aggressive tumor features, even in people who do not yet have a formal diabetes diagnosis. While the research does not prove that diabetes causes cancer to grow faster, it provides strong evidence that the two conditions are linked in a way that affects how the cancer presents itself. By understanding these connections, medical professionals can better stratify risk and ensure that patients with metabolic issues receive the attention they need to manage their colorectal cancer effectively.